Get 30% off on all global market reports with code ONLINE30 – stay updated on tariff changes, macroeconomic trends, and more!
How the Albumin Market Has Progressed: A Look Back Over the Past Few Years?
In previous years, the albumin market size has experienced significant growth. It is expected to expand from a valuation of $6.57 billion in 2024 to $7.16 billion in 2025, exhibiting a compound annual growth rate (CAGR) of 9.0%. The growth registered during the historical period is credited to advancements in biotechnology, the rising demand for plasma-derived treatments, the expanding use of albumin in pharmaceutical applications, the widespread occurrence of liver diseases, the approval of regulatory bodies for albumin-based items, and the globalization of healthcare services leading to an expanded market reach.
In the ensuing years, a robust expansion is anticipated for the albumin market, pushing its size to a staggering $9.93 billion by 2029. This growth, corresponding to a compound annual growth rate (CAGR) of 8.5%, is in direct response to various factors including the growing incidence of liver diseases, the widening integration in the field of regenerative medicine, the ballooning geriatric population, the constant advancement of diagnostic methods, the paradigm shift in healthcare facilities toward outpatient care, and the increasing awareness regarding the significance of achieving an optimal protein balance. Trends during the forecasted period to watch out for include broadening therapeutic applications, surges in utilization in drug delivery systems, escalated demand in cell culture media, progressions in personalized medicine, breakthroughs in recombinant technology, elevated understanding of hypoalbuminemia treatment, and considerable financial commitment in research and development for the creation of novel albumin-based offerings.
Claim Your Free Sample Report:
http://www.thebusinessresearchcompany.com/sample….p;type=smp
What’s Behind the Consistent Growth of the Albumin Industry?
The escalating occurrence of diabetes is anticipated to spur the expansion of the albumin market in the future. Diabetes, a metabolic ailment characterized by extended periods of high blood sugar levels, is on the rise due to factors such as poor nutrition, inadequate physical activity, hormonal disorders, and obesity. Albumin plays a critical role as a biomarker in managing diabetes, guiding insulin therapy, supervising glycemic control, aiding diagnoses, and foretelling complications like diabetic ketoacidosis (DKA). Keeping albumin levels in check is integral to effective diabetes management. For instance, in January 2022, the National Library of Medicine in the U.S stated that the worldwide prevalence of diabetes in 2021 was about 10.5%, affecting an estimated 536.6 million individuals between the ages of 20 and 79. The number is forecasted to swell to 12.2% by 2045, afflicting approximately 783.2 million individuals.
Consequently, the escalating occurrence of diabetes is anticipated to spur the expansion of the albumin market in the future.
Top Revenue-Generating Segments in the Albumin Market
The albuminmarket covered in this report is segmented –
1) By Type: Human Serum Albumin; Bovine Serum Albumin; Recombinant Albumin
2) By Application: Therapeutics; Drug Formulation And Vaccines; Component Of Media; Other Applications
3) By Sales Channel: Business-To-Consumer (B2C); Business-To-Business (B2B)
4) By End-User: Hospitals And Clinics; Pharmaceutical And Biotechnology Companies; Research Institutes
Subsegments:
1) By Human Serum Albumin: Plasma-Derived Human Serum Albumin; Recombinant Human Serum Albumin; Human Serum Albumin For Therapeutic Use (In Liver Disease, Burns); Human Serum Albumin For Drug Delivery And Research Applications
2) By Bovine Serum Albumin: Bovine Serum Albumin For Laboratory Use (In Cell Culture); Bovine Serum Albumin For Diagnostic Kits; Bovine Serum Albumin As A Stabilizer In Vaccines And Biopharmaceuticals
3) By Recombinant Albumin: Recombinant Human Albumin For Therapeutic Applications; Recombinant Albumin For Biopharmaceutical Formulation; Recombinant Albumin For Cosmetic And Personal Care Applications; Recombinant Albumin For Research And Diagnostic Applications
Access the Full Report Today:
http://www.thebusinessresearchcompany.com/report/…ket-report
What Technological Trends Are Set to Revolutionize the Albumin Market?
Leading businesses in the albumin market are moving towards innovation by producing products like recombinant albumin, devoid of animal and human origin, to more effectively cater to consumers with superior capabilities. This form of albumin is synthesized using a non-mammalian system, such as yeast, and lacks elements obtained from humans or animals. For example, in March 2023, UK’s Albumedix, a producer of recombinant human albumin (rHA), and Japan’s Heartseed Inc., a clinical-stage biotech company in the experimental stage, teamed up to introduce Recombin, a crucial excipient for Heartseed’s investigational cell therapy HS-001 production as the inaugural human clinical trial begins. This partnership is pivotal in HS-001’s evolution, carrying the promise of transforming treatments for various illnesses. Incorporating recombination in the manufacturing procedure guarantees optimal performance and reliability of the cell therapy, further consolidating its potential for therapeutic victory.
How Are Different Regions Contributing to the Albumin Market’s Growth?
North America was the largest region in the albumin market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the albumin market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
Get a Customized Version of the Report:
http://www.thebusinessresearchcompany.com/customi…p;type=smp
Which Firms Are Setting the Benchmark in the Global Albumin Market?
Major companies operating in the albumin market are Bristol-Myers Squibb Company, Thermo Fisher Scientific Inc., Takeda Pharmaceutical Company Limited, Merck KGaA, Baxter International Inc., CSL Limited, Grifols SA, Mitsubishi Tanabe Pharma Corporation, Octapharma AG, Kedrion S.p.A., Biotest AG, Jiangxi Boya Bio-Pharmaceutical Co. Ltd., BPL (Bio Products Laboratory), Kamada Ltd., Proliant Biologicals, SeraCare Life Sciences Inc., HiMedia Laboratories, Albumedix Ltd., Medxbio Pte Ltd., Ventria Bioscience Inc., China Biologic Products Holdings Inc.
Access the Complete Report:
http://www.thebusinessresearchcompany.com/purchas…x?id=16333
How Our Market Research Reports Help Maximize ROI Across Industries:
* Identify High-Growth Opportunities: Pinpoint emerging trends, untapped segments, and regional hotspots that align with your strategic goals.
* Reduce Investment Risk: Make data-driven decisions with confidence by understanding market dynamics, key drivers, and competitive threats.
* Optimize Strategic Planning: Align your product development, marketing, and expansion plans with industry forecasts and customer behaviour insights.
Americas +1 310-496-7795
Europe +44 7882 955267
Asia & Others +44 7882 955267 & +91 8897263534
News From
The Business Research Company …
Category: Industry Reports & Market Analysis Profile: The Business Research Company is a leading market research and consulting services provider. It offers over 9,500 market reports across 27 industries in 60+ geographies, providing detailed insights and forecasts. Its customised research solutions support companies in making critical decisions, while its continuous research service enhances organizational capabilities. The flagship Global Market Model database provides comprehensive market intelligence with 1,500,000 datasets covering 8,000+ mark …
This email address is being protected from spambots. You need JavaScript enabled to view it.
